title: Impact of alpha-bungarotoxin on transmitter release at the neuromuscular junction of the rat.
abstract: The drug, alpha-bungarotoxin (BTX) is believed to be a 'pure' nicotinic antagonist. Hence, use of this drug should avoid the secondary actions associated with other nicotinic antagonists. The hypothesis that the motor nerve terminal responds to the presence of acetylcholine (ACh) by releasing less transmitter was tested by examining the effects of BTX on end-plate potentials (EPPs), miniature end-plate potentials (MEPPs), and quantal release at the rat diaphragm neuromuscular junction. Analysis of EPP and MEPP amplitudes and quantal release demonstrate that BTX significantly increases transmitter release at the onset of tetanic stimulation (50 Hz). Like other nicotinic antagonists, BTX was not able to sustain enhanced quantal release during a brief train of 40 stimuli and resulted in greater decline in EPP amplitude during tetanic stimulation. The data suggests that negative feedback regulation by presynaptic autoreceptors only serves a functional role at the onset of stimulation and that other factors such as transmitter supply or adenosine regulation may serve to dominate transmitter release during maintained tetanic stimulation.
authors.affiliation: Department of Zoology, Miami University, Oxford, OH 45056, USA.
authors.forename: M A
authors.initials: MA
authors.lastname: Domet
authors.forename: C E
authors.initials: CE
authors.lastname: Webb
authors.forename: D F
authors.initials: DF
authors.lastname: Wilson
mesh_terms: D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D002038:Bungarotoxins / Q000494:pharmacology*; D003964:Diaphragm / Q000187:drug effects / Q000294:innervation / Q000378:metabolism; D004558:Electric Stimulation; D005260:Female; D066298:In Vitro Techniques; D009045:Motor Endplate / Q000187:drug effects; D009411:Nerve Endings / Q000187:drug effects / Q000378:metabolism; D009469:Neuromuscular Junction / Q000187:drug effects / Q000378:metabolism*; D018377:Neurotransmitter Agents / Q000378:metabolism*; D018733:Nicotinic Antagonists / Q000494:pharmacology*; D010791:Phrenic Nerve / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D011978:Receptors, Nicotinic / Q000187:drug effects
chemical_list: D002038:Bungarotoxins; D018377:Neurotransmitter Agents; D018733:Nicotinic Antagonists; D011978:Receptors, Nicotinic